These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36245861)

  • 1. Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.
    Hassan K; Struthers WM; Sankarabhotla A; Davis P
    Front Psychiatry; 2022; 13():992624. PubMed ID: 36245861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.
    Hull TD; Malgaroli M; Gazzaley A; Akiki TJ; Madan A; Vando L; Arden K; Swain J; Klotz M; Paleos C
    J Affect Disord; 2022 Oct; 314():59-67. PubMed ID: 35809678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review.
    Oliver PA; Snyder AD; Feinn R; Malov S; McDiarmid G; Arias AJ
    J Clin Psychiatry; 2022 Sep; 83(6):. PubMed ID: 36112599
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series.
    Bentley S; Artin H; Mehaffey E; Liu F; Sojourner K; Bismark A; Printz D; Lee EE; Martis B; De Peralta S; Baker DG; Mishra J; Ramanathan D
    Pharmacotherapy; 2022 Mar; 42(3):272-279. PubMed ID: 35122282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Ketamine in the Treatment of Psychiatric Disorders.
    Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
    Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada.
    Chrenek C; Duong B; Khullar A; McRee C; Thomas R; Swainson J
    Front Psychiatry; 2023; 14():1283733. PubMed ID: 38260793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential.
    Chubbs B; Wang J; Archer S; Chrenek C; Khullar A; Wolowyk M; Swainson J
    Front Psychiatry; 2022; 13():1016439. PubMed ID: 36465297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression.
    Skala K; Doganay K; Eder H; Mairhofer D; Neubacher K; Plener PL
    Front Psychiatry; 2023; 14():1118737. PubMed ID: 37333918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety.
    Hauser J; Sarlon J; Liwinski T; Brühl AB; Lang UE
    Front Psychiatry; 2024; 15():1327598. PubMed ID: 38322143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
    Liester M; Wilkenson R; Patterson B; Liang B
    Cureus; 2024 Apr; 16(4):e57654. PubMed ID: 38707115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
    Tamman A; Anand A; Mathew SJ
    Expert Opin Drug Saf; 2022 Jun; 21(6):745-759. PubMed ID: 35253555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
    Ahuja S; Brendle M; Smart L; Moore C; Thielking P; Robison R
    BMC Psychiatry; 2022 Oct; 22(1):634. PubMed ID: 36192794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder.
    Willms J; McCauley B; Kerr L; Presto P; Arun A; Shah N; Irby K; Strawn M; Kopel J
    Front Psychiatry; 2022; 13():1020214. PubMed ID: 36620675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.